Muscarinic supersensitivity: a possible model for the sleep disturbance of primary depression?
- PMID: 233154
- DOI: 10.1016/0165-1781(79)90023-4
Muscarinic supersensitivity: a possible model for the sleep disturbance of primary depression?
Abstract
The sleep changes induced in normal volunteers following the administration of scopolamine on 3 consecutive mornings resemble many of the abnormalities observed in the sleep of patients with primary depression: increased sleep latency and reduced rapid eye movement (REM) latency, total sleep time, and sleep efficiency. Furthermore, in a multivariate discriminant analysis--previously shown to distinguish the sleep records of depresed patients from those of normal controls and insomniac patients--the records from baseline nights were selected as normal and those after scopolamine as predominately depressed. Those observations suggest to us that muscarinic supersensitivity in normals may function as a pharmacological model for the sleep disturbances of depression.
Similar articles
-
Scopolamine-induced muscarinic supersensitivity in normal man: changes in sleep.Psychiatry Res. 1979 Jul;1(1):9-16. doi: 10.1016/0165-1781(79)90022-2. Psychiatry Res. 1979. PMID: 233155
-
The cholinergic REM induction test with RS 86 after scopolamine pretreatment in healthy subjects.Psychiatry Res. 1991 Sep;38(3):247-60. doi: 10.1016/0165-1781(91)90015-h. Psychiatry Res. 1991. PMID: 1754637
-
Differential effects of scopolamine on nocturnal cortisol secretion, sleep architecture, and REM latency in normal volunteers: relation to sleep and cortisol abnormalities in depression.Biol Psychiatry. 1989 Feb 15;25(4):403-12. doi: 10.1016/0006-3223(89)90193-5. Biol Psychiatry. 1989. PMID: 2930809 Clinical Trial.
-
[Depression and sleep--the status of current research].Fortschr Neurol Psychiatr. 1994 Dec;62(12):458-78. doi: 10.1055/s-2007-1002303. Fortschr Neurol Psychiatr. 1994. PMID: 7835818 Review. German.
-
REM sleep dysregulation in depression: state of the art.Sleep Med Rev. 2013 Oct;17(5):377-90. doi: 10.1016/j.smrv.2012.11.001. Epub 2013 Feb 5. Sleep Med Rev. 2013. PMID: 23391633 Review.
Cited by
-
Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.Biol Psychiatry. 2013 Jun 15;73(12):1156-63. doi: 10.1016/j.biopsych.2012.09.031. Epub 2012 Nov 28. Biol Psychiatry. 2013. PMID: 23200525 Free PMC article. Review.
-
Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression.Brain Struct Funct. 2008 Sep;213(1-2):93-118. doi: 10.1007/s00429-008-0189-x. Epub 2008 Aug 13. Brain Struct Funct. 2008. PMID: 18704495 Free PMC article. Review.
-
The anterior cingulate cortex may enhance inhibition of lateral prefrontal cortex via m2 cholinergic receptors at dual synaptic sites.J Neurosci. 2012 Oct 31;32(44):15611-25. doi: 10.1523/JNEUROSCI.2339-12.2012. J Neurosci. 2012. PMID: 23115196 Free PMC article.
-
Sex-Dependent Effects of Piromelatine Treatment on Sleep-Wake Cycle and Sleep Structure of Prenatally Stressed Rats.Int J Mol Sci. 2022 Sep 8;23(18):10349. doi: 10.3390/ijms231810349. Int J Mol Sci. 2022. PMID: 36142262 Free PMC article.
-
Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.Arch Gen Psychiatry. 2006 Oct;63(10):1121-9. doi: 10.1001/archpsyc.63.10.1121. Arch Gen Psychiatry. 2006. PMID: 17015814 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources